In the present work, we examined whether RHAMM could be introduced into the human monocyte-derived (mo-)DCs we use in our cancer vaccine clinical trials through mRNA electroporation, and whether these DCs then present RHAMM and activate RHAMM-specific T cells. Here, HMMR is linked to cancer.